I struggled with my weight my entire life, but my recent weight loss journey began after my second son was born in 2018.I ...

Weight loss and diabetes drugs Ozempic, Wegovy, Mounjaro and Zepbound are seen as game-changers for obesity and weight ...

A special event is aimed at answering questions and giving local residents the best information about those medications.

SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...

近年来，减肥药市场迎来了前所未有的发展热潮，尤其是礼来的热门产品Zepbound和Mounjaro更是其中的佼佼者。然而，最近的市场表现却令人担忧——礼来因销售业绩未达预期而遭遇大幅下跌，股价一度跌幅超过12%。这一现象是否意味着减肥药市场正在遭遇“撞墙”？ 一、引人注目的市场现象 减肥药作为医药领域的“摇钱树”，近年来吸引了大量投资者和消费者的关注。根据礼来的最新财报，尽管减肥药的整体需求依然存 ...

财报“爆雷”、行业巨头股价跌破关键点位，“炙手可热”的减肥药也要面临需求危机了？受热门减肥药Zepbound和Mounjaro销售不佳影响，礼来Q3营收利润皆不及预期，公司同时下调全年财务指引。受此影响，公司股价周三盘前一度大跌12%，全天收跌6%， ...

快讯摘要 【礼来公司Zepbound和Mounjaro第三季度销售额低于预期】讯，礼来公司的畅销减肥药Zepbound和糖尿病治疗药物Mounjaro第三季度的销售额低于预期 ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

据证券时报，礼来公司的畅销减肥药Zepbound和糖尿病治疗药物Mounjaro第三季度的销售额低于预期，尽管这两种药物已基本从美国的普遍短缺中恢复过来。该制药商将这一失误归咎于药品批发商削减了Zepbound和Mounjaro的库存。礼来公司的高管坚称，这些药品的潜在需求依然强劲，而且公司有足够的供应。

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

礼来Q3营收为114.4亿美元，同比增长20%，但仍低于分析师预估的121亿美元；净利润为9.7亿美元，去年同期净亏损为5740万美元，每股盈1.18美元，低于分析师预估的1.45美元。 就营收类别来看， ...

Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...